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1. INTRODUCTION 
Although movement of fatty acids between 
bilayers can occur spontaneously, the existence of 
an intracellular carrier protein was postulated in 
the early 1970’s. It has been gradually established 
that the cytosol of various mammalian cells con- 
tains a low molecular mass protein that exhibits a 
high affinity for fatty acids and their CoA esters 
and hence may participate in their intracellular 
transport and/or storage, much like albumin does 
extracellularly. These fatty acid binding proteins 
(FABPs), as they are called, are a class of 
14-15 kDa proteins that have been isolated from 
different tissues of rat, bovine and human species. 
Three structurally distinct FABP types from liver, 
heart and intestine have been thoroughly 
characterized thus far. The fatty acid binding pro- 
teins belong to a new superfamily of nonenzymic 
proteins which are characterized by structural 
homologies indicating a common ancestral gene. 
This protein family includes, in addition to the 
three mammalian FABP types, the various cellular 
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retinoid-binding proteins, the P2 protein of 
peripheral nerve myelin and the ~422 adipocyte 
protein. 
The heterogeneity of the FABPs and their en- 
dogenous ligands have been defined and numerous 
physiological functions have been proposed in a re- 
cent review [l]. In the present paper, the different 
types of FABPs, their structural prerequisites to 
act as fatty acid carriers and their tissue-specific 
expression have been analysed and their functions 
in fatty acid transport and metabolism have been 
discussed in relation to their biochemical 
characteristics. 
2. DIFFERENT TYPES OF FABPs AND 
THEIR STRUCTURAL ANALYSIS 
Of all the FABPs reported to date, perhaps the 
most thoroughly studied is the hepatic type from 
rat liver (hFABP) [2]. The protein has an isoelec- 
tric point around neutrality, yet a variety of more 
acidic ‘isoforms’ have been found, which are 
believed to result from binding different ligands. 
However, two distinct isoproteins of hFABP in the 
apoform isolated from delipidated bovine liver 
cytosol are known [3]. The cardiac-type protein 
(cFABP) was obtained from heart muscle of 
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human, rat, pig and bovine sources [4]. From the 
latter, two isoforms of cFABP with acidic isoelec- 
tric points have been isolated and characterized 
[5]. Cardiac and hepatic FABPs were clearly 
distinct with regard to their immunological 
characteristics and protein chemistry. Moreover, 
the 2 types are also different from intestinal-type 
FABP (iFABP), which is abundantly present in 
small intestinal lining cells (enterocytes) [2]. 
The primary structures of the three mammalian 
FABP types have been fully defined. Human and 
rat hFABPs contain 127 amino acids (14.3 kDa), 
whereas corresponding iFABPs as well as cFABPs 
from rat, bovine and human heart contain 132 
amino acids (14.7-15.1 kDa) [l]. Sequence 
homologies between different types of FABP are 
around 40% even when expressed in the same cell, 
but within one FABP type interspecies homologies 
up to 90% are observed. 
CD-spectroscopic data predicted an overall 
secondary structure of 12% a-helix, 46% p- 
structure, 15% &turn and 27% remainder for 
neutral hFABP from bovine liver [6]. Overwhelm- 
ing proportions of &structure have also been 
predicted for cardiac- [7] and intestinal-type pro- 
teins. Confirmation for the latter came from a re- 
cent study, where rat iFABPs were expressed in E. 
coli and subsequent X-ray crystallographic data 
revealed a P-barrel core structure that appears to 
be a common motif for hydrophobic molecule 
transporters [S]. 
3. BINDING OF LIGANDS 
Long-chain fatty acids were the only en- 
dogenous ligands that copurified with hFABP and 
cFABP when delipidation was omitted during 
isolation from mammalian organs. Up to 60% of 
endogenous long-chain fatty acids in liver and 
heart cytosols were non-covalently bound to this 
protein, of which more than 50% were polyun- 
saturated, while palmitate and stearate were the 
principal saturated fatty acids [ 11. In the case of E. 
co/i-expressed FABPs fatty acids bound to recom- 
binant iFABP were only saturated and its affinity 
for unsaturated fatty acids was indeed significantly 
lower than that of recombinant hFABP [9]. In 
vitro experiments howed, however, that FABPs 
also bind the CoA esters of long-chain fatty acids 
and modulate acyl-CoA-dependent enzymic reac- 
2 
tions. Moreover, hFABP from liver cytosols has 
been formerly addressed as Z-protein, amino- 
azodye-binding protein, sterol carrier protein 
which reflects its properties of binding a variety of 
amphiphiles [ 1,2,4]. 
Kd values of the fatty acid-FABP complexes are 
in the range of 10T7 -10m6 M [2,4,8]. A systematic 
comparison of affinities of all 3 FABP types for 
saturated and unsaturated fatty acids is not 
available to date. Lower affinities have been 
reported for acyl-CoAs and recently, it has been 
questioned whether cFABP binds acyl-CoAs at all. 
There is some controversy concerning the precise 
stoichiometry of ligand binding. Until recently it 
has been accepted that all FABPs bind one mol of 
fatty acids. However, Haunerland et al. [3] were 
the first to report that bovine hFABP binds 2 fatty 
acids, a stoichiometry supported by CD 
measurements and binding studies and now 
generally found for hepatic-type FABPs. After 
proper loading of hFABP a minimum binding of 
2 mol oleate per mol protein was reported [lo]. A 
clear 1: 1 stoichiometry was obtained for iFABP 
by binding studies and X-ray crystallography [8,9], 
whereas 1: 1 as well as 2: 1 ratios have been found 
for fatty acid/cFABP complexes [4,11]. 
The molecular basis of ligand-protein interac- 
tion is only being gradually understood. The 
binding site of neutral hFABP, when probed with 
conjugated as well as fluorescently labeled fatty 
acids, revealed that two molecules of fatty acids 
are held in close proximity in one large 
hydrophobic binding site. A role for Arg 
residue(s), located near the C-terminus of hFABP, 
was established for ionic binding of fatty acids in 
protein modification studies [6], a view challenged 
by NMR data that did not reveal electrostatic in- 
teractions with cationic residues of the protein 
[IO]. A deeply submersed fatty acid in the crevice 
of recombinant iFABP was deduced from 
crystallographic data; aromatic amino acid 
residues appeared to be in the vicinity of the fatty 
acid’s hydrocarbon chain and an Arg residue near 
its carboxylate group [8]. 
4. TISSUE-SPECIFIC EXPRESSION AND 
REGULATION OF THE FABPs 
hFABP and iFABP are expressed in con- 
siderable abundance in liver and small intestine, 
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respectively and in the latter both FABPs are ex- 
pressed. hFABP comprised 3-5070 of the cytosolic 
protein mass in adult male rat hepatocytes, 
whereas 0.2% of the translatable liver mRNA 
specified this protein. In intestinal enterocytes, 
hFABP represented 2% of jejunal and 1% of ileal 
cytosolic proteins and 3.3% of jejunal epithelial 
translatable mRNA specified this protein [2]. 
iFABP was found only in the gastrointestinal tract, 
mainly in small intestine and in detectable amounts 
in large intestine and stomach. The pattern of 
distribution of iFABP corresponds to the 
anatomical localization of dietary fat absorption 
and esterification [ 1,2]. 
The modulation of hFABP concentration by 
sex-related factors and by hypolipidemic drugs 
such as clofibrate was caused by alterations in the 
synthesis of this protein mediated at the pretransla- 
tional level, probably through regulation at the 
level of gene transcription, although hFABP- 
mRNA stabilization is also possible in liver. In 
enterocytes hFABP was hormonally and phar- 
macologically more responsive than iFABP [2]. 
Recent data disclosed that cFABP and its 
mRNA are far more widely distributed than 
hFABP or iFABP. cFABP is most abundant in 
adult heart and relatively high levels are also found 
in skeletal muscle. Distinct pattern of developmen- 
tal changes of cFABP-mRNA accumulation were 
found in heart, placenta, brain, kidney and testes, 
which insinuates a function in oxidative fatty acid 
metabolism. However, the presence of cFABP in 
brain suggests a wider role in lipid homeostasis [l]. 
5. FUNCTIONAL PROPERTIES 
Although considerable evidence indicates that 
the three types of mammalian FABPs serve distinct 
biological functions, their precise physiological 
role is yet to be elucidated. Insight into the 
physiological functions of FABPs has been gained 
from a vast array of studies on different ap- 
proaches which may be grouped as follows: 
5.1. Promoting cellular uptake of fatty acids and 
facilitating their utilization 
Significant correlations have been observed be- 
tween the tissue content of FABP and the rate of 
uptake or utilization of fatty acids particularly in 
response to dietary, hormonal and phar- 
macological manipulations. Following a long-term 
high-fat diet the cytosolic FABP content rises in 
rat liver, heart, intestine and adipose tissue. Dur- 
ing diabetes and starvation, however, the markedly 
increased hepatic fatty acid oxidation is accom- 
panied by a decrease of hFABP [ 1,2,4]. 
The utilization of oleate and its incorporation 
into triacylglycerols were greater in hepatocyte 
suspensions from adult female rats than from 
males and corresponded to a higher hFABP con- 
centration in liver cytosol of female rats. Ad- 
ministration of sex steroids to castrated rats could 
reproduce these sex differences in both fatty acid 
utilization and hFABP content [2]. Estrogen treat- 
ment has been shown to cause marked changes in 
hepatic lipid metabolism including increased syn- 
thesis of VLDL apoproteins, hFABP and 
augmented lipogenesis. Clofibrate increases 
hepatic content of hFABP as well as the uptake 
rate of fatty acids. 
FABP titers in rat liver and heart cytosols as 
determined by fatty acid binding showed a diurnal 
variation with the highest levels during the dark 
period, which may be related to the rat’s nocturnal 
feeding habits [4]. This would indicate a rapid 
turnover of FABPs and, in one instance, a half-life 
of hFABP in rat liver as low as 2 h was reported. 
In contrast, Bass and colleages determined a value 
of 3.1 days, which agrees with all experimental 
evidence that lipid and effecters of lipid 
metabolism have no immediate impact on the 
regulation of FABPs [2]. 
5.2. Protection of enzymes and cellular structures 
from detergent effects 
FABP concentrations up to 300 PM were found 
in liver and heart cytosols which always provide ex- 
cess binding sites for fatty acids and acyl-CoAs in 
the non-diseased state of the organs [4]. FABP 
may thus serve as an intracellular buffer from 
which the substrates are rapidly mobilized in 
response to the cell’s metabolic needs. The 
solubilizing effect of FABPs protects cellular 
membranes against toxic effects of fatty acids and 
acyl-CoAs and their critical micellar concentration 
is not surpassed. 
5.3. Modulation of enzyme activities 
Fatty acids and their CoA esters in their 
monomeric forms are inhibitory to a variety of en- 
3 
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zymes and transport systems. FABPs may binding sites for fatty acids and acyl-CoAs. On the 
modulate some aspects of cellular metabolism by other hand, hFABP in liver cells was detected in in- 
binding these effecters, thus attenuating their in- tracellular membranes. This membrane-associated 
hibitory actions. The ability of FABPs to prevent hFABP may be a consequence of direct hFABP- 
or reverse the feedback inhibition of fatty acid or membrane interaction that helped to target 
acyl-CoA on enzymes has been demonstrated, e.g. substrates for specific metabolic paths. Interesting- 
in the case of acetyl-CoA carboxylase and ly, cFABP and hFABP have been detected in 
mitochondrial ATP/ADP translocase from rat nuclei of corresponding cells; whether they carry a 
liver and human placental and fetal liver message related to lipid metabolism remains to be 
glucose-6-dehydrogenase [2,4,12]. established. 
A direct modulating effect of FABPs or FABP- 
substrate complexes on enzyme activities is dif- 
ficult to assess experimentally in vitro. Usually, 
conclusions were based on enhanced stimulatory 
effects observed for FABP vis-&vis albumin. En- 
zymes catalyzing acylation reactions in the course 
of phosphatidic acid and triglyceride biosynthesis 
in liver and lung microsomes have been reported to 
be stimulated by the respective FABPs. A general 
effect on long-chain transacylases, however, can- 
not be deduced as for example the acylation of 
Iysophosphatidic acid in lung microsomes was not 
affected by FABP [2,4,13]. Both stimulatory and 
inhibitory effects of hFABP and cFABP were 
observed for microsomal fatty acid activation [2]. 
Whereas FABP interacting with the enzyme- 
containing membrane could produce the 
stimulatory effect, inhibition was explained by 
competitive retainment of fatty acid on FABP in 
the soluble phase. 
6. CONCLUSION 
Long-term in vivo studies demonstrated a clear 
correlation between cytosolic FABP contents and 
cellular utilizations of fatty acids. Although many 
plausible data are available, evidence in vitro is on- 
ly circumstantial for a direct involvement of FABP 
in cellular transport and metabolism of fatty acids 
and their CoA esters. Recent knowledge on the 
structural details of FABPs indicates a common 
design for their binding of fatty acids. The expres- 
sion of different types of FABPs and the occur- 
rence of isoforms in various cells suggest an 
adaptation to specific metabolic needs of the cells. 
As the genomic organisation of FABP genes 
becomes more and more elucidated, it will be in- 
teresting to note whether a deficiency or structural 
defect of this class of proteins has any significance 
for fatty acid transport and metabolism. 
5.4. Targeting fatty acids to specific metabolic 
path ways 
In model systems FABPs enhance the transfer of 
fatty acids between microsomes, mitochondria and 
liposomes and may also remove fatty acids from 
multilamellar liposomes [ 141. 
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Self-aggregates of cFABP in heart cell cytosol 
have been proposed to transfer fatty acids to 
mitochondria for &oxidation [7]. Alternatively, 
when polyunsaturated fatty acids are retained in 
the cytosol due to high-affinity binding to cFABP, 
other fatty acids partition preferentially into 
mitochondria for activation and subsequent energy 
production. 
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